| Literature DB >> 25828303 |
Dan Xi1, TianTian Luo1, Haowei Xiong1, Jichen Liu1, Hao Lu1, Menghao Li1, Yuqing Hou1, Zhigang Guo2.
Abstract
Serum amyloid P component (SAP), also known as pentraxin-2, is a member of the pentraxin protein family with an established relationship to the immune response. In the last century, SAP has been used as a diagnostic marker in amyloidosis diagnosis and patient follow-up. SAP has been thought to have potential for treating and curing amyloidosis and fibrosis diseases. More recently, it has been shown that SAP may serve as both a diagnostic marker and a therapeutic target for many immune-related diseases, such as cardiovascular, pulmonary, nephritic, neurological and autoimmune diseases. In the cardiovascular system, SAP has been defined as the culprit in amyloidosis in the heart. SAP may also exert a protective role during the early stage of atherosclerosis and myocardial fibrosis. In noncardiovascular system diseases, SAP is being developed for the treatment of pulmonary fibrosis. In this review, we summarize SAP history, structure, and its roles in immune-related diseases in different systems with emphasis on the cardiovascular system.Entities:
Keywords: Amyloidosis; Fibrosis; Immune-related diseases; Serum amyloid P component (SAP)
Mesh：
Substances：
Year: 2015 PMID： 25828303 DOI： 10.1016/j.ijcard.2015.03.179
Source DB: PubMed Journal: Int J Cardiol ISSN： 0167-5273 Impact factor: 4.164